Affordable Access

Administration of recombinant IL-2 augments the level of serum IgM in an IL-2 deficient patient.

Authors
  • Doi, S
  • Saiki, O
  • Hara, T
  • Sugita, T
  • Ha-Kawa, K
  • Tanaka, T
  • Hara, H
  • Negoro, S
  • Yabuuchi, H
  • Kishimoto, S
Type
Published Article
Journal
European journal of pediatrics
Publication Date
Jun 01, 1989
Volume
148
Issue
7
Pages
630–633
Identifiers
PMID: 2663515
Source
Medline
License
Unknown

Abstract

A patient with ataxia telangiectasia was treated with recombinant interleukin-2 (rIL-2) and the resulting immunological effects evaluated. The patient lacked IL-2 production, and immunoglobulin synthesis was also impaired. Treatment with IL-2 selectively increased serum IgM without any significant side effects. Therapy also restored B-cell function in vitro. IgM production as well as the proliferative response to Staphylococcus aureus strain Cowan I. These results suggest that IL-2 treatment may correct both T-cell and B-cell defects.

Report this publication

Statistics

Seen <100 times